COPENHAGEN, April 8 (Reuters) - The Novo Nordisk Foundation has refiled an application to the U.S. Federal Trade Commission for approval of a $16.5 billion deal to buy Catalent, a spokesperson said on Monday. (Reporting by Jacob Gronholt-Pedersen, writing by Stine Jacobsen, editing by Anna Ringstrom)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
883.2 DKK | +0.07% | -1.62% | +26.51% |
07:03am | Europe's laggard stocks sparkle as superstars hit pause | RE |
05-08 | NOVO NORDISK : Berenberg reiterates its Neutral rating | ZD |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
883.2 DKK | +0.07% | -1.62% | 568B | ||
56.2 USD | -0.58% | +0.36% | 10.17B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.51% | 568B | |
+32.95% | 698B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.84% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B | |
-1.81% | 160B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk owner refiles U.S. application for approval of Catalent deal